All In MedTech

Device Trial Radar · NCT05380856

Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction

Sacral Neuromodulation for Patients With Multiple Sclerosis With Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial.

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 18, 2023

Primary completion

Sep 1, 2027

Study completion Sep 1, 2027

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Copenhagen; Aarhus University Hospital; Aalborg University Hospital
First posted
May 19, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD). After first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF. Period of randomization: four months. Number anticipated to be included: 60 patients

Conditions

  • Neurogenic Dysfunction of the Urinary Bladder
  • Multiple Sclerosis
  • Sacral Neuromodulation
  • Bowel Dysfunction
  • Sexual Dysfunction
  • Quality of Life

Interventions

  • Turning ON the neuromodulatorDevice

    IPG on

  • Turning OFF the neuromodulatorDevice

    IPG OFF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success of SNM for neurogenic lower urinary tract dysfunctionTime frame: Six months
  2. Male bladder functionTime frame: Six months
  3. Female bladder functionTime frame: Six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Odense University Hospital

    Odense, Fyn, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.